Skip to content

Intra-Articular Corticosteroid versus Platelet-Rich Plasma for Knee Osteoarthritis

Intra-Articular Corticosteroid versus Platelet-Rich Plasma for Knee Osteoarthritis: A Double Blind Randomized Controlled Trial on Pain Trajectories and Cartilage Matrix Integrity, with Activity-Specific Functional Correlates

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122139
Enrollment
Unknown
Registered
2026-04-09
Start date
2026-04-15
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis (KOA)

Interventions

HA+CS:Hyaluronic acid + corticosteroid knee cavity injection
HA+PRP:Hyaluronic acid + platelet-rich plasma knee joint injection

Sponsors

Songyang County Hospital of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Adults aged 40–75 years; 2.The main diagnosis is unilateral idiopathic knee osteoarthritis. 3.The diagnosis must be confirmed as Kellgren-Lawrence level II or level III by X-ray examination on X-rays of the standing before and after and the side knee joint. 4.Participants must report persistent knee joint symptoms, which are defined as pain for most days (=4 days) for at least one week in the first 3 months. 5.The baseline WOMAC pain sub-scale score =5 (0-20 scale) to ensure that there is enough symptom load to detect improvement.

Exclusion criteria

Exclusion criteria: 1.Inflammatory joint diseases (such as rheumatoid arthritis); 2.Secondary osteoarthritis (for example, caused by major trauma); 3.Symptomatic osteoarthritis of other lower limb joints that may be confused with functional evaluation; 4.History of knee joint surgery or joint replacement surgery on the affected side; 5.Inject drugs into the affected knee joint within the first 6 months; 6.Severe obesity (body mass index, BMI>35kg/square metre); 7.Patients associated with coagulation disorders, active infection, immunosuppression and patients who cannot provide consent tests; 8.Other patients who are not suitable for this study; 9. Currently participating in any other interventional clinical trial. 10. Any other condition that may compromise the safety of the subjects or the integrity of the study.

Design outcomes

Primary

MeasureTime frame
Continuous variables (0-20 points, high score = pain);

Secondary

MeasureTime frame
Continuous variables (0-100mm, high score = pain);Continuous variables (milliseconds, ms);Continuous variables (0-68 points, high score = disfunction heavy);Continuous variables (0-100 points, high score = good function);Continuous variables (number of times, high score = good function);Classified variables (existed/did not occur);

Countries

China

Contacts

Public ContactQUE QIHONG

Songyang County Hospital of traditional Chinese Medicine

13906787146@163.com+86 578 807 2216

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026